Analyst Reco. Beam Therapeutics Inc.

Equities

BEAM

US07373V1052

Real-time Estimate Cboe BZX Other stock markets 07:33:14 29/04/2024 pm IST			5-day change	1st Jan Change
22.11 ^USD	+3.41%		-7.76%	-18.33%

04/04	Beam Therapeutics Insider Sold Shares Worth $581,617, According to a Recent SEC Filing	MT
04/04	Beam Therapeutics Insider Sold Shares Worth $734,805, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Beam Therapeutics Insider Sold Shares Worth $581,617, According to a Recent SEC Filing	04/04	MT
Beam Therapeutics Insider Sold Shares Worth $734,805, According to a Recent SEC Filing	04/04	MT
Barclays Raises Price Target on Beam Therapeutics to $42 From $26, Maintains Equalweight Rating	28/02	MT
RBC Raises Price Target on Beam Therapeutics to $35 From $27 on 'More Favorable Regulatory Environment,' Keeps Sector Perform, Speculative Risk	28/02	MT
Wedbush Adjusts Beam Therapeutics' Price Target to $57 From $48, Keeps Outperform Rating	27/02	MT
JPMorgan Upgrades Beam Therapeutics to Overweight From Neutral, Raises Price Target to $40 From $38	29/01	MT
BofA Securities Downgrades Beam Therapeutics to Neutral From Buy, Price Target is $35	15/12	MT
Jefferies Downgrades Beam Therapeutics to Hold From Buy, Cuts Price Target to $30 From $75	08/12	MT
Cantor Fitzgerald Lowers Price Target on Beam Therapeutics to $32 From $56, Maintains Overweight Rating	17/23/17	MT
Credit Suisse Adjusts Beam Therapeutics' Price Target to $47 From $46, Keeps Neutral Rating	09/23/09	MT
Citigroup Adjusts Beam Therapeutics Price Target to $56 From $60, Maintains Buy Rating	09/23/09	MT
RBC Cuts Beam Therapeutics' Price Target to $32 From $42, Keeps Sector Perform Speculative Risk Rating	07/23/07	MT
Citigroup Adjusts Price Target on Beam Therapeutics to $60 From $62, Keeps Buy Rating	11/23/11	MT
Barclays Adjusts Price Target on Beam Therapeutics to $41 From $45, Keeps Equalweight Rating	11/23/11	MT
RBC Cuts Price Target on Beam Therapeutics to $42 From $50, Maintains Sector Perform, Speculative Risk Rating	11/23/11	MT
Bernstein Initiates Beam Therapeutics at Market Perform With $37 Price Target	21/23/21	MT
Wells Fargo Adjusts Price Target on Beam Therapeutics to $105 From $125, Keeps Overweight Rating	01/23/01	MT
Cantor Fitzgerald Starts Beam Therapeutics at Overweight With $62 Price Target	01/23/01	MT
SVB Securities Trims Price Target on Beam Therapeutics to $77 From $81, Maintains Outperform Rating	23/23/23	MT
BMO Capital Upgrades Beam Therapeutics to Outperform From Market Perform, Raises Price Target to $66 From $61	20/22/20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Beam CEO Andy Bromberg: Bitcoin ETFs a financialisation away from the original essence of crypto

January 31, 2024 at 12:51 am IST